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Introduction
Although survival of children with acute lymphoblastic 
leukaemia is almost 85%, outcome for the 3–5% of patients 
with Philadelphia-chromosome-positive acute lympho-
blastic leukaemia (ALL) is poor.1,2 An inter national study3 
reported results for 610 children treated with intensive 
chemotherapy without tyrosine-kinase inhibitors. 7-year 
event-free survival was 32% and overall survival was 45%. 
Matched donor allogeneic stem-cell transplantation was 
beneﬁ cial. Many groups treating adults with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia have 
noted the safety and eﬀ ectiveness of imatinib4,5 when given 
with chemo therapy.6–20 In an observational study,21 the 
Children’s Oncology Group (COG) assessed increased 
exposure to imatinib combined with chemotherapy in ﬁ ve 
cohorts. 44 children who received continuous imatinib 
from consolidation to the end of treatment, had a 3-year 
event-free survival of 80%, with acceptable toxic eﬀ ects. In 
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Summary
Background Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive 
acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is 
unknown. This study assesses the safety and eﬃ  cacy of oral imatinib in association with a Berlin–Frankfurt–Munster 
intensive chemotherapy regimen and allo geneic stem-cell transplantation for paediatric patients with Philadelphia-
chromosome-positive ALL.
Methods Patients aged 1–18 years recruited to national trials of front-line treatment for ALL were eligible if they had 
t(9;22)(q34;q11). Patients with abnormal renal or hepatic function, or an active systemic infection, were ineligible. 
Patients were enrolled by ten study groups between 2004 and 2009, and were classiﬁ ed as good risk or poor risk 
according to early response to induction treatment. Good-risk patients were randomly assigned by a web-based system 
with permuted blocks (size four) to receive post-induction imatinib with chemotherapy or chemotherapy only in a 
1:1 ratio, while all poor-risk patients received post-induction imatinib with chemotherapy. Patients were stratiﬁ ed by 
study group. The chemotherapy regimen was modelled on a Berlin–Frankfurt–Munster high-risk backbone; all received 
four post-induction blocks of chemotherapy after which they became eligible for stem-cell transplantation. The primary 
endpoints were disease-free survival at 4 years in the good-risk group and event-free survival at 4 years in the poor-risk 
group, analysed by intention to treat and a secondary analysis of patients as treated. The trial is registered with EudraCT 
(2004-001647-30) and ClinicalTrials.gov, number NCT00287105.
Findings Between Jan 1, 2004, and Dec 31, 2009, we screened 229 patients and enrolled 178: 108 were good risk and 
70 poor risk. 46 good-risk patients were assigned to receive imatinib and 44 to receive no imatinib. Median follow-up 
was 3·1 years (IQR 2·0–4·6). 4-year disease-free survival was 72·9% (95% CI 56·1–84·1) in the good-risk, imatinib 
group versus 61·7% (45·0–74·7) in the good-risk, no imatinib group (p=0·24). The hazard ratio (HR) for failure, 
adjusted for minimal residual disease, was 0·63 (0·28–1·41; p=0·26). The as-treated analysis showed 4-year disease-
free survival was 75·2% (61·0–84·9) for good-risk patients receiving imatinib and 55·9% (36·1–71·7) for those who 
did not receive imatinib (p=0·06). 4-year event-free survival for poor-risk patients was 53·5% (40·4–65·0). Serious 
adverse events were much the same in the good-risk groups, with infections caused by myelosuppression the most 
common. 16 patients in the good-risk imatinib group versus ten in the good-risk, no imatinib group (p=0·64), and 
24 in the poor-risk group, had a serious adverse event.
Interpretation Our results suggests that imatinib in conjunction with intensive chemotherapy is well tolerated and 
might be beneﬁ cial for treatment of children with Philadelphia-chromosome-positive ALL.
Funding Projet Hospitalier de Recherche Clinique-Cancer (France), Fondazione Tettamanti-De Marchi and 
Associazione Italiana per la Ricerca sul Cancro (Italy), Novartis Germany, Cancer Research UK, Leukaemia Lymphoma 
Research, and Central Manchester University Hospitals Foundation Trust.
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this group, which excluded patients with induction failure, 
outcome with matched donor allo geneic stem-cell 
transplantation was not better than chemotherapy plus 
imatinib. In a small number of patients treated with a 
high-risk chemotherapy protocol (SHOP-2005) plus 
imatinib in Spain, outcome was good compared with 
historical controls.22 Minimal residual disease at the end of 
induction is an independent predictor of outcome in 
childhood acute lymphoblastic leukaemia.23 However, in 
the COG study, minimal residual disease assessed by 
multiparameter ﬂ ow cytometry at the end of induction 
treatment, before administration of imatinib, was not 
prognostic for survival.
We report results of the European intergroup study of 
post-induction treatment of Philadelphia-chromosome-
positive ALL (EsPhALL), which is contemporary to the 
COG study. The aim was to test the safety and long-term 
eﬃ  cacy of post-induction imatinib plus chemotherapy 
compared with the standard Berlin–Frankfurt–Munster 
backbone intensive treatment, using a risk-stratiﬁ ed 
approach for treatment of patients on the basis of early 
response to therapy.24
Methods
Patients
To provide adequate statistical power, the study was 
started as a large collaborative trial. Patients were 
enrolled into this open-label, randomised trial by ten 
national study groups, mainly in Europe (AIEOP, 
BFM-G/CH, COALL, FRALLE, NOPHO, MRC, DCOG, 
CPH, PINDA, and HKPHOSG), which obtained ethics 
approval from their own institutions.
Patients aged 1–18 years recruited to national trials of 
front-line treatment for ALL were eligible if t(9;22)
(q34;q11) was present according to cytogenetics tested at 
the participating institution and the presence of a BCR-
ABL fusion transcript identiﬁ ed by real-time PCR—
detecting the transcripts for both the p190 and p210 
isoforms—or ﬂ uorescence in-situ hybridisation (FISH). 
Information about additional cytogenetic abnormalities 
was not recorded, because it was beyond the scope of the 
study. Patients with abnormal renal or hepatic function 
(grade 2–3 toxic eﬀ ects according to the National Cancer 
Institute Common Toxicity Criteria [NCI CTC]) or active 
systemic infection at the end of induction treatment were 
ineligible. Written, informed consent was obtained from 
parents or legal guardians.
After induction treatment, patients were classiﬁ ed as 
good risk or poor risk. Good-risk patients were those 
who had both early response and complete remission at 
the end of induction. Early response was deﬁ ned as 
blast cell count of less than 1000 cells per μL in 
peripheral blood after 7 days of treatment with 
prednisone and a single intrathecal dose of meth o-
trexate, or 25% or less bone marrow blast cells at day 
15, or less than 5% bone marrow blast cells at day 21, 
depending on national induction protocols. Complete 
remission was deﬁ ned as less than 5% blast cells in 
bone marrow aspirate (with absolute neutrophil count 
≥1500 cells per μL and ≥100 000 platelets per μL) and 
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Figure 1: Study design
For details of the chemotherapy regimens see appendix. C=continuation therapy. See Online for appendix
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absence of leukaemia in other organs. Poor-risk patients 
were those who did not have early response or complete 
remission at the end of induction, and received 
chemotherapy and imatinib.
Randomisation and masking
Patients classiﬁ ed as good-risk patients were randomly 
assigned to receive imatinib with chemo therapy or 
chemotherapy only. We did the randomisation with a 
centralised web-based random isation system25 with 
permuted blocks (size four) and a 1:1 allocation ratio. The 
allocation was stratiﬁ ed by study group to account for the 
diﬀ erent methods of assessment of early response. When 
a study centre identiﬁ ed a potential patient, eligibility 
was conﬁ rmed by the group data centre. The study was 
open label.
Procedures
Chemotherapy was modelled on a Berlin–Frankfurt–
Munster high-risk backbone,24 with all patients receiving 
four post-induction blocks of treatment—protocol IB, 
HR1, HR2, and HR3 (appendix)—after which they 
became eligible for allogeneic stem-cell transplantation 
in complete remission (ﬁ gure 1, appendix).1 Stem-cell 
transplantation was recommended for all poor-risk 
patients and for good-risk patients with any genotype-
matched donor. Transplant ation from both matched 
related and unrelated donors was allowed in good-risk 
patients because the two techniques seem to have much 
the same outcome in Philadelphia-chromosome-positive 
ALL as a result of improved HLA matching and 
supportive care.3,26 Patients who did not have a transplant 
had cranial irradiation and two re-induction blocks 
before continuation of treatment. Preliminary data from 
a phase 1 study27 show that daily oral imatinib is well 
tolerated in children at doses of 260–570 mg/m² per day, 
therefore we used an intermediate dose of 300 mg/m² 
per day for our study. Imatinib was given for 126 days, 
starting from the end of induction, concomitantly with 
chemotherapy during protocol IB and in an alternated 
regimen with the other protocols (ﬁ gure 1), as done in 
contemporary studies of adults (appendix).17,20
Resistance to protocol was deﬁ ned as 5% blast cells or 
more in bone marrow aspirate at the end of the third 
consolidation block of treatment for those without 
previous complete remission. Late response was deﬁ ned 
as less than 5% blast cells in bone marrow aspirate at the 
end of either protocol IB or one of three consolidation 
blocks, for patients who did not have complete remission 
at end of induction. Bone marrow relapse was deﬁ ned as 
25% blast cells or more in bone marrow, after remission.
Minimal residual disease was analysed in central 
laboratories (one for each study group) that agreed on 
standard procedures. It was assessed in bone marrow 
and peripheral blood cells collected at eight points 
(ﬁ gure 1), by quantitative real-time PCR ampliﬁ cation of 
immunoglobulin, T-cell receptor gene,28 and BCR-ABL 
fusion gene, according to guidelines.29 Few patients had 
data for the BCR-ABL fusion gene and so they were not 
included in the analysis, mainly because of scarcity of 
RNA for analysis. We report only immunoglobulin and 
T-cell receptor data measured after induction, according 
to the cutpoint usually adopted to distinguish high-risk 
patients in AIEOP-BFM ALL protocols.30,31
Serious adverse events were reported to the national 
contact person within 24 h and monitored at follow-up by 
the coordination unit (AB, MS, MGV, and PDL). Safety 
was assessed by clinical observation and weekly 
haematological and biochemical monitoring.
The primary endpoint in the good-risk group was 
disease-free survival at 4 years because the group only 
178 enrolled
108 good risk
90 randomly assigned
 44 allocated to no imatinib
  31 did not receive imatinib
  13 deviations
    9 clinical decision
    3 parents’ refusal
        1 unknown
 46 allocated imatinib
 46 received imatinib
51 excluded
 16 did not meet eligibility criteria*
 35 did not enter†
18 excluded
 10 clinical decision
 8 no consent given
 0 lost to follow-up  1 lost to follow-up§ 0 lost to follow-up
44 analysed  46 analysed 70 analysed
70 poor risk
229 patients screened
 32 received allogeneic 
      stem-cell transplantation
 12 did not receive allogeneic 
      stem-cell transplantation
  2 early failure‡
  10 clinical decision
  
 37 received allogeneic 
      stem-cell transplantation
 9 did not receive allogeneic 
      stem-cell transplantation
  1 early failure‡
  8 clinical decision
  
 59 received allogeneic 
      stem-cell transplantation
 11 did not receive allogeneic 
      stem-cell transplantation
  4 early failure‡
  7 clinical decision
  
Figure 2: Trial proﬁ le
*12 not enrolled in front-line acute lymphoblastic leukaemia protocols, two did not have relevant data, one had 
abnormal renal function, and one had active fungal infection. †For 24 patients trial protocol not approved by 
ethics committee, four because of clinical decision, three because of parents’ refusal, two because of late diagnosis 
of t(9;22), and two died during induction. ‡Early failures were deﬁ ned as relapses and deaths during continuous 
complete relapse within 5 months of ﬁ rst complete remission. §One patient lost to follow-up because of infection 
with Clostridium sp not related to imatinib (patient had liver failure, disseminated intravascular coagulation, and 
lung consolidation).
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includes patients in ﬁ rst complete remission. For poor-
risk patients the primary endpoint was event-free survival 
at 4 years. The secondary endpoint was overall survival at 
4 years. The main analyses were done by intention to 
treat; a secondary analysis was done of patients as treated.
Disease-free survival was deﬁ ned as time from 
randomisation (or date of complete remission for poor-risk 
patients) until relapse at any site, death during complete 
remission, or development of a second malignant 
neoplasm. Event-free survival was deﬁ ned as time from 
start of treatment (ie, protocol IB) to ﬁ rst failure, deﬁ ned as 
resistance, relapse, death from any cause, or second 
malignant neoplasm. Overall survival was deﬁ ned by the 
time from start of treatment to death from any cause.
Statistical analysis
The international trial data centre checked the quality of 
data and produced blinded yearly reports for the trial’s 
steering committee and interim analyses for the data 
monitoring committee.
The study aimed to recruit 140 good-risk patients, to 
provide 80% power to detect a 24% diﬀ erence in 4-year 
disease-free survival, with an expected baseline disease-
free survival of 40% (two-sided test, 5% type 1 error and a 
minimum of 2 years of follow-up), according to Lachin 
and Faulkes.32 During 2009, the steering committee 
reviewed preliminary study results and external evidence 
for the beneﬁ t of imatinib21 and decided to prematurely 
stop enrolment. Final follow-up was on Dec 31, 2010.
Observation periods were censored at date of last 
contact when no events were reported. We produced 
Kaplan-Meier curves for each endpoint (with Greenwood 
SEs33) and compared groups with the log-rank test. We 
applied the Cox model to estimate hazard ratios (HRs; 
tested according to Wald). For the regressor in the model 
we included the variables treatment and post-induction 
minimal residual disease (three categories: <5×10–⁴ cells, 
≥5×10–⁴ cells, and unknown) because of an unexpected 
imbalance of minimal residual disease in the randomised 
groups. Planned secondary analyses were by group at 
2 years after censoring patients who had transplants at 
date of stem-cell transplantation, and as-treated analyses 
counting deviations from the assigned group and 
comparing patients who actually received imatinib with 
those who did not. We calculated the probabilities of 
relapse and of death in continuous complete remission 
with the cumulative incidence estimator, thus allowing 
for competing risks, and compared them with the Gray 
test. We used the χ² test to assess the association between 
treatment group and severe adverse events. All tests were 
two sided. We did all analyses with SAS (version 9.2). 
This trial is registered with the EudraCT (2004-001647-30) 
and ClinicalTrials.gov, number NCT00287105.
Role of the funding source
Novartis provided the study drug. The sponsors had no 
role in study design, data collection, data analysis, data 
interpretation, or writing of the report. All authors had 
full access to all the data in the study and had ﬁ nal 
responsibility for decision to submit for publication.
Results
Recruitment started on Jan 1, 2004, and ended on Dec 
31, 2009. 229 patients were screened, 213 met eligibility 
criteria, and 178 (age range 1·5–17·9 years) were 
enrolled and stratiﬁ ed as good risk (108; 61%) or poor 
Good-risk, 
imatinib group 
(n=46)
Good-risk, no 
imatinib group 
(n=44)
Poor-risk 
group (n=70)
Female 17 (37%) 16 (36%) 26 (37%)
Male 29 (63%) 28 (64%) 44 (63%)
Age at diagnosis
<10 years 28 (61%) 28 (64%) 29 (41%)
≥10 years 18 (39%) 16 (36%) 41 (59%)
White blood cell count (cells per μL)
Data not available 0 2 1
<50 29 (63%) 25 (60%) 20 (29%)
50–100 6 (13%) 6 (14%) 14 (20%)
>100 11 (24%) 11 (26%) 35 (51%)
Immunophenotype
Data not available 0 0 1
Common 21 (46%) 19 (43%) 41 (59%)
Pre-B 20 (43%) 19 (43%) 19 (28%)
Pro-B 1 (2%) 0 (0%) 3 (4%)
Other B cell precursor 4 (9%) 5 (11%) 5 (7%)
T-cell lineage 0 (0%) 1 (2%) 1 (1%)
CNS involvement
Not assessable 1 (2%) 2 (5%) 4 (6%)
Yes 4 (9%) 4 (9%) 4 (6%)
No 41 (89%) 38 (86%) 62 (89%)
t(9;22)(q34;q11)
Fluorescence in-situ hybridisation only 14 (30%) 18 (41%) 23 (33%)
Real-time PCR only 10 (22%) 11 (25%) 17 (24%)
Both 22 (48%) 15 (34%) 30 (43%)
If real-time PCR, transcript detected
Data not available 7 6 7 
p190 23 (92%) 18 (90%) 31 (78%)
p210 2 (8%) 2 (10%) 9 (23%)
Early response*
Yes (peripheral blood) 23 (50%) 22 (50%) 1 (1%)
No (peripheral blood) 0 (0%) 0 (0%) 39 (56%)
Yes (bone marrow) 23 (50%) 22 (50%) 3 (4%)
No (bone marrow) 0 (0%) 0 (0%) 27 (39%)
Minimal residual disease at end of 
induction†
Data not available 16 21 23
<5×10⁴ 11 (37%) 15 (65%) 2 (4%)
≥5×10⁴ 19 (63%) 8 (35%) 45 (96%)
*Early response was assessed in bone marrow in COALL, FRALLE, MRC, and NOPHO, and in peripheral blood in the 
other groups. †Hong-Kong and PINDA did not contribute data. 
Table 1: Baseline characteristics
Articles
940 www.thelancet.com/oncology   Vol 13   September 2012
risk (70; 39%; ﬁ gure 2). Up to 2008 (when evidence for 
adults became fully available), eight of 90 good-risk 
patients (9%) refused to be assigned, in 2009, ten of 
18 eligible good-risk patients (56%) were not assigned, 
resulting in 90 good-risk patients being randomly 
assigned. More patients were older than 10 years in the 
poor-risk group than in the good-risk group and fewer 
patients had white blood cell counts of less than 50 cells 
per μL at diagnosis (table 1).
All patients except two had progenitor-B Philadelphia-
chromosome-positive acute lymphoblastic leukaemia. Of 
85 patients for whom detection of p190 and p210 was 
possible, p210 was detected more often in poor-risk 
patients than in good-risk patients.
Four patients achieved early response but not complete 
response at the end of induction and were classiﬁ ed as 
poor risk. Minimal residual disease at the end of 
induction was higher in poor-risk patients than in good-
risk patients.
Baseline characteristics were much the same in each 
good-risk group, except for post-induction minimal 
residual disease, with low levels (<5×10–⁴) more frequent 
in the good-risk, no imatinib than in the good-risk, 
imitinab (table 1). Median follow-up of the 178 enrolled 
Good-risk, imatinib group Good-risk, no imatinib group Poor-risk group
Chemotherapy 
(n=9)*
Allogeneic 
stem-cell 
transplantation 
(n=37)
Chemotherapy 
(n=12)*
Allogeneic 
stem-cell 
transplantation 
(n=32)
Chemotherapy 
(n=11)*
Allogeneic 
stem-cell 
transplantation 
(n=59)
First relapse 4 (44%) 6 (16%) 5 (42%) 7 (22%) 7 (64%) 16 (27%)
Site of ﬁ rst relapse
Bone marrow 2 (22%) 4 (11%) 4 (33%) 7 (22%) 4 (36%) 13 (22%)
Bone marrow and other 1 (11%) 2 (5%) 0 (0%) 0 (0%) 2 (18%) 2 (3%)
Extramedullary† 1 (11%) 0 (0%) 1 (8%) 0 (0%) 1 (9%) 1 (2%)
Death in continuous complete remission 0 (0%) 2 (5%) 1 (8%) 3 (9%) 2 (18%) 6 (10%)
Cause of death
Graft-versus-host disease 0 (0%) 1 (3%) 0 (0%) 2 (6%) 0 (0%) 0 (0%)
Infection 0 (0%) 1 (3%) 1 (8%) 1 (3%) 0 (0%) 4 (7%)
Other‡ 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (18%) 2 (3%)
Alive in continuous complete remission§ 0 (0%) 2 (5%) 1 (8%) 3 (9%) 2 (18%) 6 (10%)
Data are n (%). 108 of 128 randomised patients (84%) had allogeneic stem-cell transplantation after HR3, eight (6%) before HR3, and seven (5%) after additional 
consolidation (data were unavailable for ﬁ ve patients). *Includes patients who failed early—ie, relapsed or died in complete continuous remission within 5 months of 
complete remission (one relapse in the good-risk, imatinib group; one relapse and one death in the good-risk, no imatinib group; and two relapses and two deaths in the 
poor-risk group). †All in CNS, except for one in testis in the good-risk, imatinib group. ‡Other causes of death were capillary leak syndrome (n=1) and cardiac failure during 
chemotherapy (n=1). Severe autoimmune diseases (n=1) and intracranial bleeding (n=1) occurred after transplantation. §No second malignant neoplasms were reported 
during the follow-up.
Table 2: Relapses and deaths
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Figure 3: Disease-free survival and cumulative incidence of relapse and of death in continuous complete remission in good risk patients, analysed by intention to treat
(A) Disease-free survival. (B) Cumulative incidence of relapse and death continuous complete remission for patients in the good-risk group. One event in a patient in the imatinib group at 6 years after 
randomisation is omitted (died in continuous complete remission of pulmonary graft-versus-host disease after transplantation). 
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patients was 3·1 years (2·0–4·6). For these patients 
4-year event-free survival was 61·9% (95% CI 52·2–69·8) 
and 4-year  overall survival was 72·1% (95% CI 64·5–79·7). 
For the 160 patients who were randomly assigned or in 
the poor-risk group, 4-year event-free survival was 61·0% 
(95% CI 53·0–69·0) and overall survival was 72·2% 
(95% CI 64·4–80·0).
Allogeneic stem-cell transplantation was done in ﬁ rst 
complete remission in 137 of 178 (77%) patients (78 with 
good risk, 59 with poor risk) at a median of 155 days from 
ﬁ rst complete remission, and after the HR3 block for 
112 (82%) patients (table 2). The most common type of 
transplant was from HLA-matched unrelated donors in 
both risk groups (44 [56%] good risk, 27 [46%] poor risk).
At 4 years, disease-free survival was 72·9% (95% CI 
56·1–84·1) in the good-risk, imatinib group and 61·7% 
(45·0–74·7) in the good-risk, no imatinib group (p=0·24), 
with an absolute diﬀ erence of 11·2% (95% CI –9·2 to 
31·6; ﬁ gure 3A) when calculated by intention to treat. 
The HR for any event was 0·71 (95% CI 0·33–1·54; 
p=0·38) and was 0·63 (95% CI 0·28–1·41; p=0·26) when 
adjusted for minimal residual disease after induction. 
4-year overall survival was 85·1% (95% CI 69·6–93·1) in 
the good-risk, imatinib group and 72·9% (53·9–85·0) in 
the good-risk, no imatinib group (p=0·37). The HR for 
death was 0·68 (95% CI 0·26–1·81; p=0·44) and 0·59 
(0·21–1·65; p=0·31) when adjusted for minimal residual 
disease after induction.
Relapse was the most frequent event in both good-risk 
groups, involving the bone marrow in all except four 
patients and half of relapses occurred after stem-cell 
transplantation, which was done in 37 (80%) of 46 patients 
in the good-risk, imatinib group versus 32 (73%) of 
44 patients in the good-risk, no imatinib group at a 
median time of 5·3 months (IQR 4·8–6·4) versus 
5·4 months (4·7–6·1). Cumulative incidence of relapse at 
4 years was 24·8% (95% CI 11·1–38·5) in the good-risk, 
imatinib group and 29·2% (14·9–43·5) in the good-risk, 
no imatinib group (p=0·66) and all relapses occurred 
within 3 years of entry into the study (ﬁ gure 3B). After 
relapse, roughly half of patients died, mainly from disease 
progression. More deaths in continuous complete 
remission occurred in patients in the good-risk, no 
imatinib group than in the good-risk, imatinib group and 
none were related to imatinib (table 2).
When censored at stem-cell transplantation during ﬁ rst 
complete remission, 2-year disease-free survival was 
81·2% (95% CI 30·7–96·4) in the good-risk, imatinib 
group versus 65·4% (30·4–86·0) in the good-risk, no 
imatinib group (p=0·97). 2-year disease-free survival 
without censoring was 78·9% (95% CI 63·2–88·4) versus 
67·6% (51·5–79·4; appendix).
Number at risk
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Figure 5: Survival in the poor-risk group
An event that occurred after roughly 6 years is not shown (relapse in bone marrow and testis after transplantation 
in ﬁ rst complete remission).
Figure 4: Disease-free survival curves and cumulative incidence of relapse and of death in continuous complete remission for good-risk patients, analysed as treated
(A) Disease-free survival. (B) Cumulative incidence of relapse and death continuous complete remission for patients in the good-risk group. One event in a patient in the imatinib group at 6 years after 
randomisation is omitted (died in continuous complete remission of pulmonary graft-versus-host disease after transplantation).
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The as-treated analyses compared 58 good-risk patients 
who received imatinib (including 12 assigned to the 
good-risk, no imatinib group), with 31 patients who did 
not. 4-year disease-free survival was 75·2% (95% CI 
61·0–84·9) versus 55·9% (36·1–71·7), with an absolute 
diﬀ erence of 19·3% (–2·0 to 41·0; p=0·06). HR adjusted 
by post-induction minimal residual disease was 0·35 
(0·14–0·90; p=0·03; ﬁ gure 4A). The cumulative 
incidence of relapse at 4 years was 21·2% (95% CI 
9·8–32·6) for patients receiving imatinib and 34·4% 
(16·4–52·4) for those not receiving imatinib (p=0·21; 
ﬁ gure 4B).
Of the 58 patients receiving imatinib, 11 did not have a 
transplant, of whom four relapsed. Of the 31 patients who 
did not receive imatinib, nine were not transplanted. Four 
of nine relapsed and one died in continuous complete 
remission. 13 of the 18 good-risk patients not included in 
the randomisation received imatinib, although not always 
according to protocol. None relapsed and three died in 
continuous complete remission (one after stem-cell 
transplantation in ﬁ rst complete remission).
Of the 70 poor-risk patients, 35 (50%) were not in 
complete remission at the end of induction. All patients 
eventually attained complete remission; 28 after protocol 
IB, ﬁ ve after HR1, and two after HR2. 59 (84%) received 
allogeneic stem-cell transplantation during ﬁ rst com-
plete remission at a median time of 4·9 months (IQR 
4·1–5·4). 4-year event-free survival was 53·5% (95% CI 
40·4–65·0) and 4-year overall survival was 63·5% 
(95% CI 50·2–74·2; ﬁ gure 5). 35 patients who were in 
complete remission at the end of induction had a 4-year 
event-free survival of 58·5% (95% CI 40·9–76·1) versus 
48·9% (95% CI 31·5–49·1) for the remaining 35 who 
achieved complete remission at a later time (p=0·45). 
Disease-free survival at 4 years from complete remission 
was the same as event-free survival, because no patient 
was resistant to protocol.
23 patients relapsed (table 2) within 24 months of study 
entry, mostly involving bone marrow (n=21). Roughly 
70% of these patients died because of disease progression. 
Eight patients died in continuous complete remission 
and none were judged to be related to imatinib. 
Proportions of patients with the most commonly 
reported serious adverse events did not diﬀ er 
substantially between groups (p=0·64 when comparing 
good-risk patients treated with imatinib to those 
without) and were mainly related to myelosuppression 
(table 3). Infections were the most common serious 
adverse event. Minor delays (≤1 week) in administration 
of chemotherapy were more common in good-risk 
patients not receiving imatinib than those receiving 
imatinib (14/31 [45·2%] vs 13/58 [22·4%]) whereas 
major delays (>1 week) occurred in 25 of 58 (43·1%) 
patients in the good-risk, imatinib group versus six of 
31 (19·4%) patients in the good-risk, no imatinib group. 
However, this diﬀ erence was not signiﬁ cant (p=0·07). 
Poor-risk patients had similar results (20 had minor 
and 25 had major delays). 13 of 31 (41·9%) patients in 
the good-risk, no imatinib group, 26 of 58 (44·8%) 
patients in the good-risk, imatinib group, and 40 of 
70 (57·1%) patients in the poor-risk group had a dose 
decrease of more than 10% for chemotherapy and 
imatinib cumulative doses between the beginning of 
protocol IB and the end of HR3.
Good-risk, 
imatinib group 
(n=58)
Good-risk, no 
imatinib group 
(n=31)
Poor-risk 
group (n=70)
Any primary system organ class 16 (28%) 10 (32%) 24 (34%)
Infections
Fungal infection 1 (2%) 1 (3%) 4 (6%)
Localised infection 1 (2%) 2 (6%) 2 (3%)
Other infection 5 (9%) 3 (10%) 9 (13%)
Any* 7 (12%) 5 (16%) 14 (20%) 
Vascular disorders
Deep vein thrombosis 0 0 0
Nervous system disorders
Cerebral thrombosis 0 0 0
Convulsion 1 (2%) 1 (3%) 1 (1%)
Paraesthesia 0 (0%) 0 (0%) 1 (1%)
Cerebral haemorrhage 0 (0%) 0 (0%) 1 (1%)
Any 1 (2%) 1 (3%) 3 (4%)
Gastrointestinal disorders
Pancreatitis 1 (2%) 0 (0%) 0 (0%)
Gastrointestinal haemorrhage 0 (0%) 1 (3%) 0 (0%)
Any 1 (2%) 1 (3%) 0 (0%)
Psychiatric disorders
Psychotic disorder 1 (2%) 0 (0%) 0 (0%)
Skin and subcutaneous tissue disorders
Dermatitis exfoliative 0 0 0
Metabolism and nutrition disorders
Diabetes mellitus 0 0 0
Immune system disorders
Anaphylactic shock 1 (2%) 1 (3%) 0 (0%)
Musculoskeletal and connective tissue disorders
Osteonecrosis 1 (2%) 1 (3%) 0 (0%)
Cardiac disorders
Cardiac failure 0 (0%) 0 (0%) 2 (3%)
Arrhythmia 0 0 0
Any 0 0 2 (3%)
Hepatobiliary disorders
Hepatic failure 1 (2%) 1 (3%) 1 (1%)
Renal and urinary disorders
Renal failure 0 0 0
Renal impairment 1 (2%) 1 (3%) 0 (0%)
Any 1 (2%) 1 (3%) 0 (0%)
Other 7 (12%) 3 (10%) 8 (11%)
A patient with more than one adverse events in a subcategory (eg, fungal infection) is counted only once under that 
subcategory. A patient with several adverse events during treatment is counted only once. The table includes data for 
all treatment phases and allogeneic stem-cell transplantation. *Patients who had more than one subcategory of 
infection are only counted once in this row.  
Table 3: Serious adverse events
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Discussion
This study was designed to assess the eﬃ  cacy and safety 
of imatinib when added to the Berlin–Frankfurt–Munster 
chemotherapy backbone in paediatric patients with 
Philadelphia-chromosome-positive ALL. Enrolment was 
stopped in 2009, because of the results of the COG study21 
and unwillingness of clinicians and families to enrol after 
numerous publications on data for adults.19 Although the 
study is not powered to fully address the primary study 
aim, important conclusions can be derived.
All patients enrolled achieved complete remission, 
whereas previous reports of patients treated with the 
same chemotherapy backbone note that as many as 
10% of patients were resistant to treatment.3 All poor-
risk patients not in complete remission after induction 
had complete remission with imatinib during consoli-
dation treatment. Disease-free survival was better in the 
good-risk, imatinib group than in the no imatinib 
group, despite the diﬀ erence in minimal residual 
disease at baseline, which favoured patients not 
receiving imatinib. Only the as-treated analysis showed 
a better outcome for imatinib-treated patients after 
adjustment for diﬀ erences in minimal residual disease 
(although with the caveat of potential selection bias). 
Additionally, toxic eﬀ ects did not diﬀ er signiﬁ cantly 
between groups. Detailed, graded data for adverse 
events were not collected.
In a historical cohort of 286 patients, 4-year disease-free 
survival was 42·3% (95% CI 36·4–48·2); less than in our 
study (table 4). In the same cohort, 61% of patients were 
transplanted in ﬁ rst complete remission. Mortality related 
to transplantation diminished with time, accounting for 
14% in the historical data and 9% in our study. In the 
historical cohort, poor-risk patients who had early 
response assessed by peripheral blood had a worse 
outcome than those who were assessed by bone marrow 
early response.3 This ﬁ nding is supported by data from 
the historical cohort and our study, although the 
diﬀ erence was not signiﬁ cant in our study (table 4).
Our results are concordant with those of the COG 
study21 and provide evidence of long-term beneﬁ t of 
treatment with imatinib for all patient groups (panel). 
However, EsPhALL has several diﬀ erences from the 
COG AALL0031 study. COG reported that use of imatinib 
after induction negated the prognostic eﬀ ect of end-of-
induction minimal residual disease. In EsPhALL, early 
response to chemotherapy continued to be predictive—
poor-risk patients still have an unfavourable outcome 
compared with good-risk patients. Patients with poor 
response to monotherapy with steroids as measured by 
blast cell count in peripheral blood, compared with bone 
marrow assessment early in induction, have a worse 
outcome (table 4), supporting historical ﬁ ndings.3 In 
view of the diﬀ erent induction protocols used in each 
study, inter pretation of this variation is diﬃ  cult. The 
prednisone poor-response group might be characteristic 
of the most highly resistant group of patients with 
Philadelphia-chromosome-positive ALL. Whether start-
ing imatinib (or a second generation tyrosine-kinase 
inhibitor) during induction would cancel the negative 
eﬀ ect of poor early response with steroids is still unclear.
The central role of allogeneic stem-cell transplantation 
was established in a pre-imatinib large cohort of patients.3 
However, COG reported21 that allogeneic stem-cell 
transplantation provides no beneﬁ t compared with 
treatment with intensive continuous imatinib (cohort 5). 
This ﬁ nding, albeit from a small number of patients, 
holds true with longer follow-up (Schultz K, COG, 
personal communication). In EsPhALL, about 80% of 
enrolled patients had allogeneic stem-cell transplantation, 
Historical data3 EsPhALL p value 
for DFS
n DFS (%; SE) ASCT in 
ﬁ rst CR 
(n; %)
Treatment-
related mortality 
from ASCT in 
ﬁ rst CR (n; %)
n DFS (%; SE) ASCT in 
ﬁ rst CR 
(n; %)
Treatment-
related mortality 
from ASCT in 
ﬁ rst CR (n; %)
Overall 286 42·3% (3·0%) 174 (61%) 25 (14%) 178 61·9% (4·1%) 137 (77%) 12 (9%) 0·0008
Poor risk 64 29·7% (6·3%) 43 (67%) 6 (14%) 70 53·5% (6·4%) 59 (84%) 6 (10%) 0·0092
Poor risk (early response 
in peripheral blood)
15 15 events (one 
at risk at 2 years)
7 (47%) 3 (43%) 39 43·6% (8·7%)* 32 (82%) 4 (13%) ··
Poor risk (early response 
in bone marrow)
49 38·8% (7·1%)* 36 (73%) 3 (8%) 27 60·8% (9·8%)* 23 (85%) 2 (9%) ··
Good risk 200 47·6% (3·6%) 115 (58%) 17 (15%) 90† 67·1% (5·3%) 69 (77%) 5 (7%) 0·0104
No imatinib ·· ·· ·· ·· 44 61·7% (7·6%) ·· ··
Imatinib ·· ·· ·· ·· 46 72·9% (7·1%) ·· ·· 0·0141‡
Analyses of the historical cohort were done for the groups who later entered EsPhALL (AIEOP, BFM, COALL, DCOG, FRALLE, UK, NOPHO). This cohort includes 319 patients, of 
whom 31 (9·7%) were resistant and two (0·6%) died in induction, leaving 286 patients in ﬁ rst CR at the end of the protocol-speciﬁ ed induction period. 22 of 286 patients are 
not classiﬁ ed by risk because early response was unknown. DFS is at 4 years unless otherwise stated. DFS=disease-free survival. ASCT=allogeneic stem-cell transplantation. 
CR=complete remission. *At 3 years. †18 good risk patients are excluded because they were not assigned. ‡For historical, good risk versus good risk, imatinib.
Table 4: Comparison of outcome from EsPhALL with historical data
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with the limitation that a common policy of 
administration of tyrosine-kinase inhibitors after trans-
plantation was not adopted. We do not know whether 
transplantation or tyrosine-kinase inhibitors explain the 
improvement compared with historical controls. In both 
good-risk and poor-risk groups, the few patients who 
received imatinib but not stem-cell transplantation, 
excluding those who failed before the median time to 
transplantation, had a poorer outcome (three of nine 
good-risk patients and ﬁ ve of seven poor-risk patients 
relapsed). However, this ﬁ nding is limited by the small 
number of patients who did not have a transplant. That 
concomitant use of tyrosine-kinase inhibitors earlier, 
more continuously, or for longer, might negate the 
requirement for myelo ablative therapy should be 
investigated further. In this context, serial analysis of 
minimal residual disease might help to select patients 
who can be treated with intensive chemotherapy 
protocols including a tyrosine-kinase inhibitor but 
without allogeneic stem-cell transplantation.
Our data support further investigation of new tyrosine-
kinase inhibitors in conjunction with the established 
chemotherapy backbone for treatment of children with 
Philadelphia-chromosome-positive ALL. The EsPhALL 
network is assessing the eﬀ ect of earlier, continuous, and 
longer exposure to imatinib and use of a second 
generation tyrosine-kinase inhibitor. Possible next steps 
are assessments of whether exposure to tyrosine-kinase 
inhibitors can change the intensity of chemotherapy and 
the use of transplantation in ﬁ rst remission.
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